Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | LITAF | Q99732 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.30 |
| ▸ | CCND1 | P24385 | 2/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186166 | 0.86 | PDE1A (0.32) | PDE4D | |
| SCHEMBL27186086 | 0.85 | JAK1 (0.35) | JAK1LRRK2JAK2JAK3TNF | |
| SCHEMBL27186115 | 0.81 | JAK1 (0.34) | JAK1LRRK2JAK2JAK3CDK4 | |
| SCHEMBL27186309 | 0.72 | BRD4 (0.39) | LRRK2 | |
| SCHEMBL27186123 | 0.71 | PDE4B (0.35) | PDE4B | |
| SCHEMBL27186269 | 0.67 | NPC1 (0.30) | LRRK2 | |
| SCHEMBL27186151 | 0.66 | PDE1B (0.38) | PDE4D | |
| SCHEMBL30481822 | 0.65 | ALOX5AP (0.31) | — | |
| SCHEMBL15770814 | 0.64 | DGAT1 (0.35) | — | |
| SCHEMBL30853341 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2022187266-A1 | NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | JAK1 1440/4885LRRK2 858/4885JAK2 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.